extracellular matrix economy includes inhibition of expression of collagen α1(I) gene, together with inhibition of transcription of NF-κB and inhibition of collagenase type IV production.

2. (amended) The method of Claim 1, wherein regulation of the extracellular matrix economy includes inhibition of expression of collagen α1(I) gene and promotion of activity of *cKrox* transcription factor, together with inhibition of transcription of NF-κB and inhibition of collagenase type IV production.

3. (amended) The method of Claim 2, wherein the regulation of the extracellular matrix economy includes inhibition of expression of collagen α1(I) gene, and promotion of activity of *cKrox*, together with inhibition of transcription of NF-κB and inhibition of collagenase type IV production, and decreasing release of cytokines IL-1β and TNFα, substantially without affecting expression of TGF-β.

A1 cont.

4. (amended) The method of Claim 1, wherein the regulation of the extracellular matrix economy includes decreasing expression of HSP47 in parallel to inhibition of expression of collagen α1(I) gene, inhibition of expression of NF-κB, inhibition of collagenase type IV production, and decreasing release of cytokines IL-1β and TNFα, substantially without affecting an expression of TGF-β.

5. (amended) The method of any of Claims 1 to 4, wherein said effector is a quinazolinone derivative.

6. (amended) The method of Claim 5, wherein said quinazolinone derivative is a member of a group having a formula:



wherein:

$R_1$ is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy;

$R_2$ is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy;

$R_3$ is a member of the group consisting of hydrogen and lower alkenoxy; and

*n* is either 1 or 2;

and pharmaceutically acceptable salts thereof.

7. (amended) The method of Claim 6, wherein said compound is Halofuginone and pharmaceutically acceptable salts thereof.

8. (amended) A method for inhibition of at least one pathological process associated with tissue trauma, comprising the step of administering to a subject in need thereof a pharmaceutically effective amount of an effector in combination with a pharmaceutically acceptable carrier, wherein said effector regulates the extracellular matrix economy in order to inhibit at least one pathological process associated with tissue trauma, wherein regulation of the extracellular matrix economy includes inhibition of expression of collagen α1(I) gene, together with inhibition of transcription of NF-κB and inhibition of collagenase type IV production.

9. (amended) The method of Claim 8, wherein regulation of the extracellular matrix economy includes inhibition of expression of collagen α1(I) gene and promotion of activity of *cKrox* transcription factor, together with inhibition of transcription of NF-κB and inhibition of collagenase type IV production.

10. (amended) The method of Claim 9, wherein the regulation of the extracellular matrix economy includes inhibition of expression of collagen α1(I) gene, and promotion of activity of *cKrox*, together with inhibition of transcription of NF-κB, inhibition of collagenase type IV production and decreasing release of cytokines IL-1β and TNFα, substantially without affecting expression of TGF-β.

A' cont.

11. (amended) The method of Claim 8, wherein said effector decreases an expression of HSP47 in parallel to inhibition of expression of collagen α1(I) gene, inhibits expression of NF-κB, inhibits collagenase type IV production and decreases release of cytokines IL-1β and TNFα, substantially without affecting expression of TGF-β.

12. (amended) The method of any of Claims 8 to 11, wherein said effector is a quinazolinone derivative.

13. (amended) The method of Claim 12, wherein said quinazolinone derivative is a member of a group having a formula:



wherein:

$R_1$ is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy;

$R_2$ is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy;

$R_3$ is a member of the group consisting of hydrogen and lower alkenoxy; and

*n* is either 1 or 2;

and pharmaceutically acceptable salts thereof.

14. (amended) The method of Claim 13, wherein said effector is Halofuginone and pharmaceutically acceptable salts thereof.

15. (amended) The method of any of Claims 8 to 14, wherein the at least one pathological process is selected from the group consisting of cancers, fibrotic conditions including but not limited to hepatic fibrosis and cirrhosis, chronic inflammatory disease, renal fibrosis, pulmonary fibrosis, cardiac fibrosis, neo-angiogenesis, formation of adhesion, psoriasis, keloids, hypertrophic scars, and a pathological condition which can be ameliorated, reduced or otherwise treated by an effector capable of regulating the extracellular matrix economy.

16. (amended) A method for inhibiting cell proliferation enabled by a deposition of an extracellular matrix, comprising the step of administering to a subject in need thereof a pharmaceutically effective amount of a compound having a formula:




A1 cont.

wherein:

$R_1$ is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;

$R_2$ is a member of the group consisting of hydroxy, acetoxy and lower alkoxy;

$R_3$ is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl;

*n* is either 1 or 2;

and pharmaceutically acceptable salts thereof.

17. (amended) A method for treating cardiac fibrosis, comprising the step of administering to a subject in need thereof a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carrier, the compound being a member of a group having a formula:



A1 cont.

wherein:

$R_1$ is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl, and lower alkoxy;

$R_2$ is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy;

$R_3$ is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; and

*n* is either 1 or 2;

and pharmaceutically acceptable salts thereof.

18. (amended) The method of Claim 17, wherein the compound is Halofuginone.

A2

21. (amended) A method for substantially preventing cardiac fibrosis, comprising the step of administering to a subject at risk of developing cardiac fibrosis a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carrier, the compound being a member of a group having a formula: